Aileron Therapeutics
NASDAQ: RNTXCambridge, US · Founded 2025 · Delaware corporation · 17 employees on LinkedIn · 2 known investors
Find your way into Aileron Therapeutics
36 people in our graph share verified history with the Aileron Therapeutics team — schools, employers, funds. One of them is your warm intro.
Klaus Breinerunlockedknows Manuel Aivado · together at University of Düsseldorf (overlapped)
×9knows the team · via University of Düsseldorf
×2knows the team · via Aileron Therapeutics
Aileron Therapeutics is a clinical-stage biopharmaceutical company developing peptide and protein-based therapies for rare lung and fibrosis diseases. The company is primarily advancing LTI-03, a peptide derived from the Cav1 protein for idiopathic pulmonary fibrosis, which has completed Phase 1b testing and is now in Phase 2 clinical development.
Founders & leadership
MA
Manuel AivadoinExecutiveManuel Aivado is an executive in biopharmaceuticals with experience in R&D, finance, and business development, and previously worked as a physician with board certification in internal medicine, hematology, and medical oncology in Germany. He conducted research at Harvard Medical School's Libermann Lab and has authored over 50 peer-reviewed publications and multiple patent applications.
BW
Brian WindsorinPresident and Chief Executive Officer; Director
Board
CW
SL
Seth L. HarrisonBoard director
RJ
Reinhard J. AmbrosBoard director
JA
Joseph A. Yanchik IIIinCo-Founder, CEO & Director2005–2018Venture Partner at Apple Tree Venture Management Llc
BM
Brian M. Gallagher, Jr.Board director
AS
Armen ShanafeltBoard director
SK
Scott KapnickBoard director
EP
Enrico PetrilloBoard director
JH
John H. McArthurBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$68.2M disclosed across 3 rounds · 2014–2023
▶$18.3MraisedNov 2023 · 15 investors · BiotechnologyRule 506(b)
▶$18.3MraisedNov 2023 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alan MussoDirector
- Reinhard J. AmbrosDirector
- Nolan Sigal, M.D., Ph.D.Director
- William FaireyDirector
- Josef H. von RickenbachDirector
- Manuel Alves-Aivado, M.D., Ph.D.Executive Officer, Director
- Brian Windsor, Ph.D.Executive Officer
- Susan L. DrexlerExecutive Officer
- Offering amount
- $18.3M
- Amount sold
- $18.3M
- Sales commissions
- $752.8K
- Placement agents
- Arcadia Securities, LLC, Clear Street LLC
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$30.1MraisedJan 2017 · 11 investors · BiotechnologyRule 506(b)
▶$30.1MraisedJan 2017 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Manuel AivadoExecutive Officer
- Caleb WinderDirector
- Seth L. HarrisonDirector
- John H. McArthurDirector
- Reinhard J. AmbrosDirector
- Joseph A. Yanchik IIIExecutive Officer, Director
- Brian M. Gallagher, Jr.Director
- Armen ShanafeltDirector
- Scott KapnickDirector
- Offering amount
- $40M
- Amount sold
- $30.1M
- First sale
- Dec 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$19.8MraisedOct 2014 · 13 investors · BiotechnologyRule 506(b)
▶$19.8MraisedOct 2014 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Joseph A. Yanchik IIIExecutive Officer, Director
- Seth L. HarrisonDirector
- Brian M. Gallagher, Jr.Director
- Armen ShanafeltDirector
- Reinhard J. AmbrosDirector
- Scott KapnickDirector
- John H. McArthurDirector
- Enrico PetrilloDirector
- Offering amount
- $33M
- Amount sold
- $19.8M
- First sale
- Oct 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Aileron Therapeutics do?
- Aileron Therapeutics is a clinical-stage biopharmaceutical company developing peptide and protein-based therapies for rare lung and fibrosis diseases. The company is primarily advancing LTI-03, a peptide derived from the Cav1 protein for idiopathic pulmonary fibrosis, which has completed Phase 1b testing and is now in Phase 2 clinical development.
- Who are Aileron Therapeutics's investors?
- Aileron Therapeutics's investors include Excel Venture Management, Novartis Venture Fund.
- How much funding has Aileron Therapeutics raised?
- Aileron Therapeutics has disclosed $68.2M raised across 3 rounds.
- Where is Aileron Therapeutics headquartered?
- Aileron Therapeutics is headquartered in Cambridge, US.